Lv01
0 积分 2023-12-19 加入
EZH2-mediated development of therapeutic resistance in cancer
2小时前
待确认
The functions of EZH2 in immune cells: Principles for novel immunotherapies
7小时前
已完结
Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs)
7小时前
已完结
Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia
9小时前
求助中
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
13天前
已完结
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
13天前
已完结
Pharmacokinetic interaction between SHR2554 and fluconazole: A single-center, open-label and one-sequence crossover phase I trial in healthy Chinese subjects
28天前
已完结
[Management strategies for chronic liver disease-related thrombocytopenia]
1个月前
已完结
儿童和青少年银屑病诊断标准
2个月前
已关闭
The relationship of aplastic anemia and PNH
2个月前
已完结
皖公网安备34019202002308
